Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMPCPR is a synthetic purine ribonucleoside monophosphate analog with the chemical formula C16H25N5O13P2 and a molecular weight of approximately 557.34 g/mol. It is also known as alpha-beta methylene ADP-ribose. This compound is classified as an experimental small molecule and has not been approved for any clinical use or indication. Its structure mimics that of adenosine diphosphate ribose (ADP-ribose), suggesting potential utility in biochemical research related to nucleotide metabolism or enzyme inhibition studies; however, no specific mechanism of action or therapeutic application has been established in humans[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AMPCPR.